FDA codifies multiple De Novo device classifications, sharpening 510(k) pathway planning

Policy signal

FDA’s recent Federal Register actions show a practical regulatory-intelligence trigger for medtech companies: several prior De Novo classifications have now been codified as Class II device types with special controls. The notices cover orthopedic, ear/nose/throat, hematology and pathology, and dental device areas, including absorbable metallic bone fixation fasteners, hemi-shoulder ceramic head/metallic stem prostheses, resorbable calcium salt bone void fillers containing a single approved aminoglycoside antibacterial, oropharyngeal electrical stimulators, von Willebrand factor assays, and intraoral cooling devices.

The signal is not simply that FDA classified multiple device types. In several cases, FDA is formalizing device-specific special controls in codified classification language. For regulatory-affairs and submissions teams, that can turn a general pathway assessment into a more concrete exercise: determine whether a product fits the device type, assess whether a 510(k) pathway may be available, and map the evidence package against each applicable special control.

Why this matters for RA and submissions teams

For manufacturers and sponsors in adjacent device spaces, the immediate action is portfolio mapping. Teams should check whether any marketed, planned, or pipeline products fall within, near, or outside one of the newly codified device types. If a product is close enough to the classified device type, the classification may affect predicate strategy, product-code mapping, submission planning, labeling, testing, and risk-control documentation.

The same Federal Register publication period also included FDA’s guidance on its intent to exempt certain unclassified medical devices from premarket notification requirements. That guidance adds another action point: companies with unclassified devices should verify whether any products fall within the listed product codes and whether current 510(k) assumptions remain appropriate.

Taken together, the classification orders and exemption guidance point to two parallel workflows. For newly codified Class II device types, teams should build special-control traceability. For affected unclassified devices, teams should reassess whether a 510(k) is expected or whether FDA’s current enforcement position changes the submission plan.

Practical watchpoints

• Portfolio classification check: Re-check whether existing or planned products align with the newly codified device descriptions, indications, technology characteristics, materials, or product codes.
• Predicate and pathway strategy: For products near the newly classified device types, assess whether the Class II classification may support a 510(k) pathway based on substantial equivalence.
• Special-controls traceability: Build or update a matrix linking each applicable special control to design inputs, verification and validation evidence, clinical or non-clinical testing, labeling, and risk controls.
• Evidence-gap assessment: Compare current development plans and submission evidence against the codified controls before assuming an existing package is sufficient.
• Orthopedic portfolio impact: The June 5 actions include multiple orthopedic device types, making orthopedic classification monitoring a near-term priority.
• IVD and non-orthopedic spillover: The June 1 actions show the pattern is not limited to implants or orthopedic products; it also covers hematology/pathology, ENT, and dental device categories.
• Unclassified-device strategy: For products still treated as unclassified, check whether FDA’s June 2026 exemption guidance applies before locking in 510(k) assumptions.
• Internal documentation: Update classification rationales, regulatory strategy memos, predicate searches, and submission planning records where affected products are identified.

What to monitor next

Regulatory teams should track the codified classification language associated with each affected device type and compare it against internal product-classification rationales. Teams should also monitor how FDA applies the special controls in future 510(k) reviews, especially where the new classification could serve as a predicate category.

For unclassified devices, teams should review FDA’s exemption guidance and confirm whether any products fall within the listed product codes. If they do, the practical question is whether the current submission plan should change in light of FDA’s stated intent not to enforce premarket notification requirements for those devices while the exemption process is pending.

The near-term workflow is straightforward: identify affected device families, update pathway and predicate assumptions, map applicable special controls, assess evidence gaps, and flag any products whose regulatory strategy depends on unclassified-device treatment.

Sources

• Federal Register — “Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener” - Federal Register — “Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability” - Federal Register — “Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis” - Federal Register — “Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial” - Federal Register — “Medical Devices; Ear, Nose, and Throat Devices; Classification of the Oropharyngeal Electrical Stimulator” - Federal Register — “Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay” - Federal Register — “Medical Devices; Dental Devices; Classification of the Intraoral Cooling Device”